대유행 신종인플루엔자 A (H1N1)의 역학, 임상 소견 및 치료
Epidemiology, clinical manifestations, and management of pandemic novel Influenza A (H1N1)
2
조회
0
다운로드
31
인용
0
참고문헌
키워드
초록
Since the first case with swine origin influenza A (H1N1) infection has been described in Mexico and the United States in April 2009, novel influenza A (H1N1) virus has been spread to all over the world. WHO has officially declared the outbreak to be an influenza pandemic by 11 June. The number of human cases and death of pandemic A (H1N1) 2009 is still increasing substantially in many countries with widespread community transmission. The natural course of novel influenza A (H1N1) still appears to be generally mild and mostly recovered. It predominantly affects children and young adults with relative sparing of older age groups, supporting a theory that older people have some cross-reactive antibodies to novel influenza A (H1N1) from previous infection or immunization. People with chronic medical conditions and pregnancy are more likely to be hospitalized with or dead from the novel influenza A (H1N1). Antiviral treatment by using neuraminidase inhibitors (oseltamivir, zanamivir) is recommended mainly for all hospitalized patients with novel influenza (H1N1) and patients who are at higher risk for seasonal influenza complications. Continued pandemic preparedness, flexible response and careful monitoring are essential because influenza viruses are unpredictable. This article reviews the current epidemiology, clinical manifestations, and management of pandemic novel influenza A (H1N1).
Abstract
Since the first case with swine origin influenza A (H1N1) infection has been described in Mexico and the United States in April 2009, novel influenza A (H1N1) virus has been spread to all over the world. WHO has officially declared the outbreak to be an influenza pandemic by 11 June. The number of human cases and death of pandemic A (H1N1) 2009 is still increasing substantially in many countries with widespread community transmission. The natural course of novel influenza A (H1N1) still appears to be generally mild and mostly recovered. It predominantly affects children and young adults with relative sparing of older age groups, supporting a theory that older people have some cross-reactive antibodies to novel influenza A (H1N1) from previous infection or immunization. People with chronic medical conditions and pregnancy are more likely to be hospitalized with or dead from the novel influenza A (H1N1). Antiviral treatment by using neuraminidase inhibitors (oseltamivir, zanamivir) is recommended mainly for all hospitalized patients with novel influenza (H1N1) and patients who are at higher risk for seasonal influenza complications. Continued pandemic preparedness, flexible response and careful monitoring are essential because influenza viruses are unpredictable. This article reviews the current epidemiology, clinical manifestations, and management of pandemic novel influenza A (H1N1).
참고문헌 (27)
- WHO, "Influenza-like illness in the United States and Mexico", ~ (2009)
- WHO, "World now at the start of 2009 influenza pandemic", ~ (2009)
- Garten RJ, "Antigenic and genetic characteristics of swine-origin 2009 A (H1N1) influenza viruses circulating in humans", Science, 325, pp.197~201 (2009)
- Zimmer SM, "Historical perspective—emergence of influenza A", N Engl J Med, 361, pp.279~285 (2009)
- WHO, "Pandemic", ~ (2009)
- WHO, "Changes in reporting requirements for pandemic (H1N1) 2009 virus infection", ~ (2009)
- WHO, "New influenza A (H1N1) virus: global epidemiological situation", Weekly Epidemiological Record, 84, pp.249~256 (2009)
- WHO, "Pandemic (H1N1) 2009 briefing note 4", ~ (2009)
- CDC, "Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine", MMWR, 58, pp.521~524 (2009)
- Fraser C, "Rapid Pandemic Assessment Collaboration. Pandemic potential of a novel strain of influenza A (H1N1): early findings", Science, 324, pp.1557~1561 (2009)
- Nishiura H, "Transmission potential of the new influenza A (H1N1) virus and its age-specificity in Japan", Euro Surveill, 14 (2009)
- Garske T, "Assessing the severity of the novel influenza A", H1N1 pandemic, 2009, pp.339, ~
- Itoh Y, "In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses", Nature (2009)
- Senanayake SN, "Swine flu update: bringing home the bacon", MJA, 191, pp.1~3 (2009)
- WHO, "Influenza", ~ (2009)
- Kaufman MA, "Life-threatening respiratory failure from H1N1 influenza", MJA, 191, pp.214~216 (2009)
- CDC, "Neurologic complications associated with novel influenza A (H1N1) virus infection in children--Dallas", MMWR, 58, pp.773~778 (2009)
- "Press release #42-09: community transmission of H1N1 flu appears to decline in New York City. New York City Department of Health and Mental"[URL]
- CDC, "Interim guidance for screening for swine-origin influenza A (H1N1) by state and local health departments, hospitals, and clinicians in regions with few or no reported cases of swine influenza A", ~ (2009)
- CDC, "Interim guidance on specimen collection, processing, and testing for patients with suspected swine-origin influenza A (H1N1) virus infection", ~ (2009)
- Ginochio CC, "Evaluation of multiple test methods for the detection of the novel 2009 influenza A (H1N1) during the New York City outbreak", J Clin Virol, 45, pp.191~195 (2009)
- Faix DJ, "Rapid-test sensitivity for novel swine-origin influenza A(H1N1) virus in humans", N Engl J Med, 29 (2009)
- Reuters, "Roche finds 1st case of H1N1 resistance to Tamiflu", ~ (2009)
- Reuters, "UPDATE 2-Japan finds first case of H1N1 resistant to Tamiflu", ~ (2009)
- CDC, "Interim guidance on antiviral recommendations for patients with confirmed or suspected swine influenza A (H1N1) virus infection and close contacts", ~ (2009)
- CDC, "Interim guidance—pregnant women and swine influenza: considerations for clinicians", ~ (2009)
- CDC, "Novel influenza A(H1N1) virus infections among healthcare personnel - United States", MMWR, 58, pp.641~645 (2009)